Email this article 
COMPARATIVE ANALYSIS OF THE THERAPEUTIC EFFICACY OF PROSPIDINE AND CISPLATIN IN NEOADJUVANT INTRAVESICAL CHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
- Authors: Shabunina T.I.1, Selivanov S.P.2, Udud E.V.3, Kladiev A.A.4, Barysheva E.V.1, Kovalik T.A.1, Isaeva S.N.1
-
Affiliations:
- Therapeutic Diagnostic Center, Tomsk
- Therapeutic Diagnostic Center, Tomsk Siberian State Medical University, Russian Agency for Health Care, Tomsk
- Research Institute of Pharmacology, Tomsk Research Center, Siberian Branch, Russian Academy of Medical Sciences
- Biotechnology Company TNK, Moscow
- Issue: Vol 7, No 4 (2011)
- Pages: 32-36
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCER
- Published: 30.12.2011
- URL: https://oncourology.abvpress.ru/oncur/article/view/217
- DOI: https://doi.org/10.17650/1726-9776-2011-7-4-32-36
- ID: 217
Cite item
Full Text
Abstract
Objective: to evaluate the antitumor efficiency of the intravesical administration of prospiridine versus cisplatin in the treatment of nonmuscle invasive bladder cancer (NMIBC).
Subjects and methods. The therapeutic effect of neoadjuvant intravesical chemotherapy (CT) was comparatively analyzed in 74 patients with transitional cell NMIBC. Thirty-four patients were given prospidine in a single dose of 200 mg to the total dose of 4000 mg; 40 patients received cisplatin in a single dose of 20 mg to the total dose of 500 mg.
Results. There was a preponderance of moderate dysuretic manifestations (55 %) during CH with prospidine and mild cystitis (62.5 %) during that with cisplatin. In the prospidine group, mild leukopenia was observed in 5 (14.7 %) patients receiving intravesical CT with prospidine and in none patients treated with cisplatin. In the same group, 11.7 and 23.5 % achieved complete or partial regression, respectively. The total effect of intravesical CT with prospidine was 32.4 % and that with cisplatin was 50 % (complete or partial regression was seen in 22.5 and 27.5 %, respectively).
Conclusion. The study has demonstrated that intravesical CT with prospidine is effective and well tolerated and may be recommended for the treatment of NMIBC.
About the authors
T. I. Shabunina
Therapeutic Diagnostic Center, Tomsk
Email: siotrec@ldc.tom.ru
Russian Federation
S. P. Selivanov
Therapeutic Diagnostic Center, TomskSiberian State Medical University, Russian Agency for Health Care, Tomsk
Author for correspondence.
Email: siotrec@ldc.tom.ru
Russian Federation
E. V. Udud
Research Institute of Pharmacology, Tomsk Research Center, Siberian Branch, Russian Academy of Medical Sciences
Email: siotrec@ldc.tom.ru
Russian Federation
A. A. Kladiev
Biotechnology Company TNK, Moscow
Email: siotrec@ldc.tom.ru
Russian Federation
E. V. Barysheva
Therapeutic Diagnostic Center, Tomsk
Email: siotrec@ldc.tom.ru
Russian Federation
T. A. Kovalik
Therapeutic Diagnostic Center, Tomsk
Email: siotrec@ldc.tom.ru
Russian Federation
S. N. Isaeva
Therapeutic Diagnostic Center, Tomsk
Email: siotrec@ldc.tom.ru
Russian Federation
References
Supplementary files
